A detailed history of Tower Research Capital LLC (Trc) transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 26,287 shares of VERV stock, worth $155,093. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,287
Previous 24,762 6.16%
Holding current value
$155,093
Previous $120,000 5.83%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.4 - $7.86 $6,710 - $11,986
1,525 Added 6.16%
26,287 $127,000
Q2 2024

Aug 13, 2024

BUY
$4.76 - $12.79 $111,959 - $300,833
23,521 Added 1895.33%
24,762 $120,000
Q1 2024

May 15, 2024

SELL
$10.81 - $17.96 $1,599 - $2,658
-148 Reduced 10.66%
1,241 $16,000
Q4 2023

Feb 13, 2024

SELL
$8.84 - $18.7 $6,470 - $13,688
-732 Reduced 34.51%
1,389 $19,000
Q3 2023

Nov 14, 2023

SELL
$11.42 - $20.82 $16,307 - $29,730
-1,428 Reduced 40.24%
2,121 $28,000
Q2 2023

Aug 14, 2023

SELL
$13.34 - $19.9 $37,138 - $55,401
-2,784 Reduced 43.96%
3,549 $66,000
Q1 2023

May 09, 2023

BUY
$14.3 - $24.01 $5,133 - $8,619
359 Added 6.01%
6,333 $91,000
Q4 2022

Feb 10, 2023

SELL
$17.85 - $40.7 $2,945 - $6,715
-165 Reduced 2.69%
5,974 $116,000
Q3 2022

Nov 10, 2022

BUY
$15.63 - $41.49 $59,628 - $158,284
3,815 Added 164.16%
6,139 $211,000
Q2 2022

Aug 15, 2022

SELL
$11.14 - $23.17 $16,710 - $34,755
-1,500 Reduced 39.23%
2,324 $35,000
Q1 2022

May 12, 2022

SELL
$20.92 - $39.36 $42,363 - $79,704
-2,025 Reduced 34.62%
3,824 $87,000
Q4 2021

Feb 14, 2022

BUY
$31.94 - $54.82 $151,683 - $260,340
4,749 Added 431.73%
5,849 $216,000
Q3 2021

Nov 15, 2021

BUY
$46.0 - $73.99 $50,600 - $81,389
1,100 New
1,100 $52,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $354M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.